Dr Reddy's rises as Nomura flags near-term biologics milestones
Shares rose as much as 1.57% after Nomura said the company awaits US FDA clearance for its biologics plant and possible approval of biosimilar Abatacept. Nomura also cited the relaunch of semaglutide in November and FY27 pen sales guidance of 6 million-7 million.